<DOC>
	<DOCNO>NCT01026194</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety MP-513 ( Teneligliptin ) combination thiazolidinedione ( pioglitazone ) patient type 2 Diabetes 12 week administration evaluate safety efficacy MP-513 combination thiazolidinedione extension treatment 52 week .</brief_summary>
	<brief_title>Efficacy Safety Study MP-513 Combination With Thiazolidinedione Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Patients 20 75 year old Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug Patients whose HbA1c 6.5 % 10.0 % Patients take Thiazolidinedione diabetes 16 week administration investigational drug Patients administer diabetes therapeutic drug prohibit concomitant use within 12 week administration investigational drug . Patients type 1 diabetes , diabetes mellitus cause pancreas impairment , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients accept treatment arrhythmias Patients serious diabetic complication Patients excessive alcohol addict Patients severe hepatic disorder severe renal disorder . Patients pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>